Mylan, the second-largest US generic drug firm made pharma news headlines with its growing interest in the Hyderabad-based SMS PharmaThe pharma giant is in late-stage talks with SMS to acquire its manufacturing units for lucrative cancer therapy drugs — both raw materials and finished drugs — and others as further reported in pharma news.
“The two companies are in the final stages of negotiations and a deal may be finalized shortly.
The part of the business Mylan proposes to buy from SMS Pharma is one of the most advanced oncology facilities in the country, providing almost end-to-end solutions in cancer therapies.
Some of them manufacture active pharma ingredients (APIs) while a part also deals with finished formulations including a range of injectables,” a banker told FE.
The banker said though there was no final agreement on price yet, a deal could be in the range of R160-200 crore.
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity